

REMARKS

The Examiner has mailed a restriction requirement for pending Claims 41-47, 52-55 and 68, and listed the following group classifications:

Group	Claim(s)	Description
I	41-47 & 52-54	methods of detecting non-positive stranded RNA viruses
II	55 & 68	methods for inhibiting human coronavirus 229E using a protease inhibitor

Applicants hereby elect to prosecute the claims of Group I, *without traverse*, with pending Claims 41-47 and 52-54 reading upon the elected group.

In addition, the Examiner alleges that the claims are directed to more than one species of generic invention, and has therefore required election of individual species for examination purposes.

Species	Members
virus of Claim 42	influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, or metapneumovirus
virus of Claims 46	togavirus, flavivirus, coronavirus, or picornavirus
inhibitor of Claim 54	actinonin, glycyrrhizin, or E64D

Applicants hereby elect the following species and subspecies for examination purposes: influenza virus, influenza A virus, coronavirus and E64D, with Claims 41-43, 46, 47, 52-54 reading upon the elected group and species. Applicants assert their intention to retain the right to rejoinder, and respectfully remind the Examiner that upon allowance of a generic claim, that Applicants are entitled to consideration of claims to additional species that depend from or otherwise include the limitations of the allowable generic claim.

Moreover, Applicants respectfully request consideration of the references listed on the Information Disclosure Statement submitted herewith, before the mailing of a first substantive Office Action. However, should the Examiner believe that a telephone interview would aid in

the prosecution of this application, Applicants encourage the Examiner to call the undersigned collect.

Dated: April 28, 2008



Christine A. Lekutis
Registration No. 51,934

MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105
415.904.6500